Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.27 Million CHF | -82.74% |
| 2022 | 24.76 Million CHF | 1.5% |
| 2021 | 24.4 Million CHF | 11.94% |
| 2020 | 21.8 Million CHF | 11.71% |
| 2019 | 19.51 Million CHF | 3.5% |
| 2018 | 18.85 Million CHF | -1.29% |
| 2017 | 19.1 Million CHF | -24.14% |
| 2016 | 25.17 Million CHF | -12.64% |
| 2015 | 28.82 Million CHF | -23.38% |
| 2014 | 37.61 Million CHF | 71.06% |
| 2013 | 21.99 Million CHF | -26.42% |
| 2012 | 29.88 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 2.69 Million CHF | -89.11% |
| 2023 Q3 | 2.69 Million CHF | -88.91% |
| 2023 Q2 | 24.32 Million CHF | 0.0% |
| 2023 Q1 | 24.32 Million CHF | -1.81% |
| 2023 Q4 | 4.27 Million CHF | 58.58% |
| 2022 Q1 | 25.77 Million CHF | 5.62% |
| 2022 FY | 24.76 Million CHF | 1.5% |
| 2022 Q3 | 24.76 Million CHF | -3.91% |
| 2022 Q4 | 24.76 Million CHF | -0.0% |
| 2022 Q2 | 25.77 Million CHF | 0.0% |
| 2021 Q3 | 24.4 Million CHF | -13.39% |
| 2021 Q4 | 24.4 Million CHF | 0.0% |
| 2021 FY | 24.4 Million CHF | 11.94% |
| 2021 Q1 | 28.17 Million CHF | 29.24% |
| 2021 Q2 | 28.17 Million CHF | 0.0% |
| 2020 Q3 | 21.8 Million CHF | 16.6% |
| 2020 Q4 | 21.8 Million CHF | 0.0% |
| 2020 FY | 21.8 Million CHF | 11.71% |
| 2020 Q1 | 18.69 Million CHF | -4.2% |
| 2020 Q2 | 18.69 Million CHF | 0.0% |
| 2019 Q1 | 17.69 Million CHF | -6.13% |
| 2019 Q4 | 19.51 Million CHF | 0.0% |
| 2019 Q2 | 17.69 Million CHF | -0.0% |
| 2019 FY | 19.51 Million CHF | 3.5% |
| 2019 Q3 | 19.51 Million CHF | 10.27% |
| 2018 Q4 | 18.85 Million CHF | 0.0% |
| 2018 Q2 | 26.32 Million CHF | 0.0% |
| 2018 Q1 | 26.32 Million CHF | 37.82% |
| 2018 FY | 18.85 Million CHF | -1.29% |
| 2018 Q3 | 18.85 Million CHF | -28.37% |
| 2017 Q2 | 22.39 Million CHF | 0.0% |
| 2017 FY | 19.1 Million CHF | -24.14% |
| 2017 Q3 | 19.1 Million CHF | -14.7% |
| 2017 Q4 | 19.1 Million CHF | 0.0% |
| 2017 Q1 | 22.39 Million CHF | -11.06% |
| 2016 Q4 | 25.17 Million CHF | 0.0% |
| 2016 FY | 25.17 Million CHF | -12.64% |
| 2016 Q3 | 25.17 Million CHF | -10.11% |
| 2016 Q2 | 28.01 Million CHF | 0.0% |
| 2016 Q1 | 28.01 Million CHF | -2.81% |
| 2015 FY | 28.82 Million CHF | -23.38% |
| 2015 Q1 | 34.29 Million CHF | -8.82% |
| 2015 Q2 | 34.29 Million CHF | 0.0% |
| 2015 Q4 | 28.82 Million CHF | 0.0% |
| 2015 Q3 | 28.82 Million CHF | -15.97% |
| 2014 Q4 | 37.61 Million CHF | 0.0% |
| 2014 Q1 | 20.89 Million CHF | -4.97% |
| 2014 Q2 | 20.89 Million CHF | 0.0% |
| 2014 Q3 | 37.61 Million CHF | 80.01% |
| 2014 FY | 37.61 Million CHF | 71.06% |
| 2013 Q4 | 21.99 Million CHF | 0.0% |
| 2013 Q1 | 26.27 Million CHF | -12.1% |
| 2013 FY | 21.99 Million CHF | -26.42% |
| 2013 Q2 | 26.27 Million CHF | 0.0% |
| 2013 Q3 | 21.99 Million CHF | -16.29% |
| 2012 FY | 29.88 Million CHF | 0.0% |
| 2012 Q4 | 29.88 Million CHF | 0.0% |
| 2012 Q3 | 29.88 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -15485.609% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 92.755% |
| Neon Bloom, Inc. | 1.22 Million USD | -248.683% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -428.639% |
| Qrons Inc. | 1.48 Million USD | -187.201% |
| Regen BioPharma, Inc. | 5.45 Million USD | 21.658% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.1% |
| BioStem Technologies, Inc. | 15.9 Million USD | 73.117% |
| Skye Bioscience, Inc. | 14.07 Million USD | 69.617% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -9465.957% |
| Rebus Holdings, Inc. | 5.24 Million USD | 18.436% |
| CSL Limited | 18.62 Billion USD | 99.977% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 94.293% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 91.494% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2025.937% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 54.832% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 91.979% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 55.379% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -914.214% |
| SQZ Biotechnologies Company | 50.03 Million USD | 91.455% |
| Intellipharmaceutics International Inc. | 12 Million USD | 64.396% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -11.013% |
| Mesoblast Limited | 188.44 Million USD | 97.731% |
| Marizyme, Inc. | 26.67 Million USD | 83.972% |
| Genus plc | 485 Million USD | 99.118% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 26.821% |
| Pharming Group N.V. | 244.07 Million USD | 98.248% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -112.703% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -69.914% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -12.516% |
| ContraFect Corporation | 32.53 Million USD | 86.857% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -115.797% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -11.703% |
| IMV Inc. | 37.93 Million USD | 88.728% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 63.699% |
| MultiCell Technologies, Inc. | 1617.67 USD | -264206.07% |
| ONE Bio Corp. | 27.49 Million USD | 84.45% |
| Accustem Sciences Inc. | 1.07 Million USD | -296.168% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 94.477% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -102.149% |
| Q BioMed Inc. | 8.13 Million USD | 47.429% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 94.845% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 16.915% |
| Biomind Labs Inc. | 1.49 Million USD | -185.304% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.399% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 52.715% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 76.767% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -198.188% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2908.973% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 25.588% |
| GB Sciences, Inc. | 5.41 Million USD | 21.079% |
| Alpha Cognition Inc. | 7.16 Million USD | 40.325% |
| HST Global, Inc. | 593.59 Thousand USD | -620.292% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -239.551% |
| Halberd Corporation | 728.71 Thousand USD | -486.728% |
| Enzolytics Inc. | 365.26 Million USD | 98.829% |
| Agentix Corp. | 2.51 Million USD | -70.305% |
| Resverlogix Corp. | 67.39 Million USD | 93.656% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -409.77% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.039% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -149.452% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 82.722% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 64.08% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -16.655% |
| AVAX Technologies, Inc. | 3.99 Million USD | -7.057% |
| Zenith Capital Corp. | 27.56 Thousand USD | -15408.724% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.678% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1691.548% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -14.495% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -527.994% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -57.676% |
| Kadimastem Ltd | 3.5 Million USD | -21.99% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -6288.262% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -820.079% |
| LadRx Corporation | 2.2 Million USD | -94.299% |
| Cell Source, Inc. | 15.8 Million USD | 72.951% |
| Regen BioPharma, Inc. | 5.45 Million USD | 21.658% |
| NovAccess Global Inc. | 7.86 Million USD | 45.608% |
| Affymax, Inc. | 8.87 Million USD | 51.803% |
| Itoco Inc. | 1.65 Million USD | -158.633% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -108.407% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 29.317% |
| Mobile Lads Corp. | 1.31 Million USD | -225.513% |
| CytoDyn Inc. | 127.89 Million USD | 96.657% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -10128.953% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -172.961% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 61.29% |
| SYBLEU INC | 681.41 Thousand USD | -527.461% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 29.93% |
| International Stem Cell Corporation | 5.27 Million USD | 18.977% |
| Bioxytran, Inc. | 3.24 Million USD | -31.577% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -583.212% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 7.397% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 89.571% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 80.797% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -111.1% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 21.95% |
| Neutra Corp. | 973.52 Thousand USD | -339.186% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 85.264% |
| PureTech Health plc | 125.58 Million USD | 96.595% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -13.8% |
| IXICO plc | 1.9 Million USD | -124.997% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 79.173% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.862% |
| CSL Limited | 18.62 Billion USD | 99.977% |
| Cellectis S.A. | 249.36 Million USD | 98.285% |